CD4 and myeloid sarcoma: We found that genes, strongly induced in MS patients treated with IFN-β, are expressed at lower levels in untreated MS patients with increased CD4+ T-cell reactivity to MBP than in untreated MS patients without detectable reactivity to MBP.